ClinicalTrials.gg
CompletedNCT07844343Updated Oct 15, 2026

A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema

A Phase 2 interventional study of SB15 PFS in Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO and Diabetic Macular Oedema, sponsored by Samsung Bioepis Co., Ltd.. Completed at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
49th of 66
33 · median 55
Started
2026
with 3 others
Phase 2
7 of 66
none open now
Registered
66th of 66
by date

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 49th largest by enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 66th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB15 PFS with intravitreal injection to trial participants with nAMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema (DME).

Read the detailed description

HCPs will prepare and administer intravitreal injections of SB15 2 mg delivered via PFS to trial participants on Day 1 and safety follow-up will be assessed until Day 7.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Macular Oedema Secondary to RVO
  • Diabetic Macular Oedema
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (Key)

  • Neovascular AMD, macular oedema secondary to RVO (branch RVO or central RVO), or DME in the study eye
  • Best Corrected Visual Acuity (BCVA) of ≥20/400 (letter score of ≥19) in the study eye and ≥20/800 (letter score of ≥4) in the fellow eye using original series Early Treatment Diabetic Retinopathy Study (ETDRS) charts or 2702 series Number charts at Screening and at Day 1
  • Study eye deemed to be indicated for continued aflibercept IVT therapy at the discretion of the retina specialist, and IP administration to be performed at the retina specialist's judgment

Exclusion Criteria: (Key)

  • History of and/or current intraocular inflammation (any grading from trace and greater is excluded), including non-infectious uveitis, infectious uveitis, or scleritis, or history of sterile inflammatory reaction after the past IVT injections with any agent in either eye
  • Active or suspected infectious disease (ocular or periocular) in either eye at Screening or at Day 1
  • History of excessive bleeding and recurrent haemorrhages, including any prior excessive intraocular bleeding or haemorrhages after IVT injection or intraocular procedures in either eye
  • History of massive subconjunctival haemorrhages of concern reported by the trial participant after an IVT injection in either eye
  • Current vitreous haemorrhage in the study eye
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    SB15 PFS

    Trial participants received a single dose of SB15 PFS containing 2 mg aflibercept in 0.05 mL solution.

    Combination Product: SB15 PFS

Interventions

  • Combination productSB15 PFS

    SB15 provided in a pre-filled syringe (PFS) containing 2 mg aflibercept in 0.05 mL for intravitreal injection

    Also known as: aflibercept

06

What researchers measure

Primary outcomes

  1. Percentage of Successful Task Completions on All of the 12 tasks

    A total of 12 tasks were evaluated, and the percentage of HCPs' successful completions on all of the 12 tasks was measured.

    Time frame: Day 1

  2. Incidence of ocular adverse events (AEs)

    Time frame: Day 1 to Day 7

Secondary outcomes

  1. Percentage of Successful Completion on Each of 12 tasks

    Time frame: Day 1

  2. Incidence of AEs and serious adverse events (SAEs)

    Time frame: From Day 1 to Day 7

07

Study locations

3 sites
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, South Korea
  • Kim's Eye Hospital
    Seoul, South Korea
  • Nune Eye Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 0 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
Sep 7, 2026
Primary completionActual
Sep 22, 2026
CompletionActual
Sep 22, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Oct 15, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844343
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 7, 2026
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion